Relay Therapeutics, Inc. (RLAY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-9M 0 9M 18M 27M Q3 '21: 666K Q4 '21: 567K Q1 '22: 419K Q2 '22: 365K Q3 '22: 344K Q4 '22: 253K Q1 '23: 226K Q2 '23: 119K Q3 '23: 25.2M Q4 '23: -1K Q1 '24: 10M Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 7.7M Q2 '25: 677K Q3 '25: 0 Q4 '25: 7M Q1 '26: 3M Q2 '26: 350K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '21: -61M Q4 '21: -67.7M Q1 '22: -62.7M Q2 '22: -77.8M Q3 '22: -85.9M Q4 '22: -72.9M Q1 '23: -101.2M Q2 '23: -106M Q3 '23: -73.6M Q4 '23: -92.2M Q1 '24: -90.4M Q2 '24: -100.8M Q3 '24: -96.4M Q4 '24: -85M Q1 '25: -84.9M Q2 '25: -76.8M Q3 '25: -80.4M Q4 '25: -60.6M Q1 '26: -78.6M Q2 '26: -90.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -60.8M Q4 '21: -67.5M Q1 '22: -62M Q2 '22: -76.8M Q3 '22: -84.2M Q4 '22: -67.5M Q1 '23: -94.2M Q2 '23: -98.5M Q3 '23: -65.7M Q4 '23: -83.5M Q1 '24: -81.4M Q2 '24: -92.2M Q3 '24: -88.1M Q4 '24: -76M Q1 '25: -77.1M Q2 '25: -70.4M Q3 '25: -74.1M Q4 '25: -54.9M Q1 '26: -73.3M Q2 '26: -83.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -53.2M Q4 '21: -39.7M Q1 '22: -49.2M Q2 '22: -57.1M Q3 '22: -66.1M Q4 '22: -57.1M Q1 '23: -67.1M Q2 '23: -68.6M Q3 '23: -75.4M Q4 '23: -89.2M Q1 '24: -50.3M Q2 '24: -65.8M Q3 '24: -75.1M Q4 '24: -57.9M Q1 '25: -73.2M Q2 '25: -55.3M Q3 '25: -62.1M Q4 '25: -44.9M Q1 '26: -51.1M Q2 '26: -54.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-105M -70M -35M 0 35M 70M 105M Q1 '21: 46.2M Q2 '21: -28.5M Q3 '21: -54.9M Q4 '21: -40.6M Q1 '22: -52M Q2 '22: -59M Q3 '22: -68.2M Q4 '22: -59.4M Q1 '23: -69M Q2 '23: -70.1M Q3 '23: -76M Q4 '23: -89.3M Q1 '24: -52.1M Q2 '24: -65.8M Q3 '24: -75.3M Q4 '24: -57.9M Q1 '25: -73.6M Q2 '25: -55.3M Q3 '25: -62.1M Q4 '25: -44.9M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q3 '21: 92.7M Q1 '22: 108.3M Q2 '22: 108.6M Q3 '22: 110.9M Q1 '23: 121.3M Q2 '23: 121.7M Q3 '23: 122.2M Q1 '24: 130.8M Q2 '24: 132.8M Q3 '24: 140.2M Q1 '25: 169.2M Q2 '25: 171.3M Q3 '25: 172.4M Q1 '26: 179.8M Q2 '26: 202.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '21: 6.42 Q4 '21: -3.85 Q1 '22: -3.95 Q2 '22: -2.56 Q3 '22: -2.66 Q4 '22: -2.59 Q1 '23: -2.80 Q2 '23: -2.90 Q3 '23: -2.68 Q4 '23: -2.80 Q1 '24: -2.64 Q2 '24: -2.52 Q3 '24: -2.61 Q4 '24: -2.36 Q1 '25: -2.20 Q2 '25: -1.92 Q3 '25: -1.72 Q4 '25: -1.61 Q1 '26: -1.56 Q2 '26: -1.56 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.